Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Operating Expenses for 9 consecutive years, with $66.4 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses fell 17.23% year-over-year to $66.4 million; the TTM value through Mar 2026 reached $305.8 million, up 11.59%, while the annual FY2025 figure was $319.7 million, 30.39% up from the prior year.
  • Operating Expenses hit $66.4 million in Q1 2026 for Bicycle Therapeutics, down from $72.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $89.5 million in Q2 2025 and bottomed at $31.2 million in Q1 2022.
  • Average Operating Expenses over 5 years is $57.6 million, with a median of $56.1 million recorded in 2023.
  • Year-over-year, Operating Expenses soared 76.08% in 2022 and then dropped 17.23% in 2026.
  • Bicycle Therapeutics' Operating Expenses stood at $35.4 million in 2022, then skyrocketed by 68.28% to $59.6 million in 2023, then grew by 19.82% to $71.4 million in 2024, then rose by 1.81% to $72.7 million in 2025, then fell by 8.66% to $66.4 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $66.4 million, $72.7 million, and $77.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.